Revance Therapeutics (RVNC) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Revance Therapeutics Revenue Highlights

Latest Revenue (Y)

$234.04M

Latest Revenue (Q)

$58.83M

Main Segment (Y)

Development Services

Revance Therapeutics Revenue by Period

Revance Therapeutics Revenue by Year

Date	Revenue	Change
2023-12-31	$234.04M	76.55%
2022-12-31	$132.56M	70.40%
2021-12-31	$77.80M	407.65%
2020-12-31	$15.32M	3610.65%
2019-12-31	$413.00K	-88.92%
2018-12-31	$3.73M	1323.28%
2017-12-31	$262.00K	-12.67%
2016-12-31	$300.00K	-
2015-12-31	$300.00K	-21.67%
2014-12-31	$383.00K	-37.93%
2013-12-31	$617.00K	-13.95%
2012-12-31	$717.00K	28.73%
2011-12-31	$557.00K	-

Revance Therapeutics generated $234.04M in revenue during NA 2023, up 76.55% compared to the previous quarter, and up 6276.21% compared to the same period a year ago.

Revance Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$58.83M	-10.04%
2024-06-30	$65.39M	25.90%
2024-03-31	$51.94M	-25.59%
2023-12-31	$69.80M	22.94%
2023-09-30	$56.78M	-2.34%
2023-06-30	$58.13M	17.84%
2023-03-31	$49.33M	-1.18%
2022-12-31	$49.92M	72.05%
2022-09-30	$29.02M	2.28%
2022-06-30	$28.37M	12.30%
2022-03-31	$25.26M	-2.66%
2021-12-31	$25.95M	31.43%
2021-09-30	$19.75M	5.00%
2021-06-30	$18.80M	41.39%
2021-03-31	$13.30M	19.46%
2020-12-31	$11.13M	190.30%
2020-09-30	$3.83M	1182.61%
2020-06-30	$299.00K	415.52%
2020-03-31	$58.00K	-34.83%
2019-12-31	$89.00K	93.48%
2019-09-30	$46.00K	100.00%
2019-06-30	-	-100.00%
2019-03-31	$278.00K	-42.92%
2018-12-31	$487.00K	-79.38%
2018-09-30	$2.36M	244.31%
2018-06-30	$686.00K	255.44%
2018-03-31	$193.00K	421.62%
2017-12-31	$37.00K	-50.67%
2017-09-30	$75.00K	-
2017-06-30	$75.00K	-
2017-03-31	$75.00K	-
2016-12-31	$75.00K	-
2016-09-30	$75.00K	-
2016-06-30	$75.00K	-
2016-03-31	$75.00K	-
2015-12-31	$75.00K	-
2015-09-30	$75.00K	-
2015-06-30	$75.00K	-
2015-03-31	$75.00K	-
2014-12-31	$75.00K	-
2014-09-30	$75.00K	-
2014-06-30	$75.00K	-52.53%
2014-03-31	$158.00K	-48.87%
2013-12-31	$309.00K	95.57%
2013-09-30	$158.00K	110.67%
2013-06-30	$75.00K	-
2013-03-31	$75.00K	-35.90%
2012-12-31	$117.00K	-

Revance Therapeutics generated $58.83M in revenue during Q3 2024, up -10.04% compared to the previous quarter, and up 101.19% compared to the same period a year ago.

Revance Therapeutics Revenue Breakdown

Revance Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Development Services	$7.10M	$5.70M	$2.00M	$400.00K	$3.70M

Revance Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 22: Development Services (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19	Mar 19
Product	$58.83M	$65.33M	$51.72M	$54.11M	$100.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration Revenue	$1.05M	$100.00K	$217.00K	$3.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Service	-	-	-	$2.66M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Development Services	-	-	-	-	$100.00K	$100.00K	$900.00K	$1.00M	$1.70M	$3.60M	$1.70M	$1.10M	$1.40M	$1.50M	$900.00K	$800.00K	$300.00K	$100.00K	$100.00K	$300.00K

Revance Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (98.24%), and Collaboration Revenue (1.76%).

Revance Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
AMLX	Amylyx Pharmaceuticals	$380.79M	$416.00K
APLS	Apellis Pharmaceuticals	$366.28M	$176.57M
IMCR	Immunocore	$249.43M	$75.40M
BPMC	Blueprint Medicines	$249.38M	$128.18M
RVNC	Revance Therapeutics	$234.04M	$58.83M
ACLX	Arcellx	$110.32M	$26.03M
STOK	Stoke Therapeutics	$8.78M	$4.89M
PLRX	Pliant Therapeutics	$1.58M	-
KRTX	Karuna Therapeutics	$654.00K	-
NUVL	Nuvalent	-	-
DAWN	Day One Biopharmaceuticals	-	$20.07M
DMAC	DiaMedica Therapeutics	-	-
CERE	Cerevel Therapeutics	-	-
MDGL	Madrigal Pharmaceuticals	-	$62.17M
TERN	Terns Pharmaceuticals	-	-
VTYX	Ventyx Biosciences	-	-
ETNB	89bio	-	-
AKRO	Akero Therapeutics	-	-

RVNC Revenue FAQ

What is Revance Therapeutics’s yearly revenue?

Revance Therapeutics's yearly revenue for 2023 was $234.04M, representing an increase of 76.55% compared to 2022. The company's yearly revenue for 2022 was $132.56M, representing an increase of 70.40% compared to 2021. RVNC's yearly revenue for 2021 was $77.8M, representing an increase of 407.65% compared to 2020.

What is Revance Therapeutics’s quarterly revenue?

Revance Therapeutics's quarterly revenue for Q3 2024 was $58.83M, a -10.04% decrease from the previous quarter (Q2 2024), and a 3.61% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $65.39M, a 25.90% increase from the previous quarter (Q1 2024), and a 12.48% increase year-over-year (Q2 2023). RVNC's quarterly revenue for Q1 2024 was $51.94M, a -25.59% decrease from the previous quarter (Q4 2023), and a 5.28% increase year-over-year (Q1 2023).

What is Revance Therapeutics’s revenue growth rate?

Revance Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 200.83%, and for the last 5 years (2019-2023) was 56568.28%.

What are Revance Therapeutics’s revenue streams?

Revance Therapeutics's revenue streams in c 22 are Development Services

What is Revance Therapeutics’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Revance Therapeutics was Development Services. This segment made a revenue of $7.1M, representing 100.00% of the company's total revenue.